Journal of International Oncology››2016,Vol. 43››Issue (8): 570-573.doi:10.3760/cma.j.issn.1673-422X.2016.08.003
Previous ArticlesNext Articles
Pan Yukai
Online:
2016-08-08Published:
2016-07-05Contact:
Pan Yukai, Email: 845386454@qq.com E-mail:845386454@qq.comPan Yukai. Expression and clinical significance of microRNA-148a in patients with non-small cell lung cancer[J]. Journal of International Oncology, 2016, 43(8): 570-573.
[1] Dimou A, Papadimitrakopoulou V. Non-small cell lung cancer beyond biomarkers: the evolving landscape of clinical trial design[J]. J Pers Med, 2014, 4(3): 386-401. DOI: 10.3390/jpm4030386. [2] Stella GM, Luisetti M, Pozzi E, et al. Oncogenes in non-small cell lung cancer: emerging connections and novel therapeutic dynamics[J]. Lancet Respir Med, 2013, 1(3): 251-261. DOI: 10.1016/S2213-2600(13)70009-2. [3] Vijayvergia NSP, Denlinger CS. Survivorship in non-small cell lung cancer: challenges faced and steps forward[J]. J Natl Compr Canc Netw, 2015, 13(9): 1151-1161. [4] Ma R, Wang C, Wang J, et al. miRNA-mRNA interaction network in non-small cell lung cancer[J]. Interdiscip Sci, 2015, In press. DOI: 10.1007/s12539-014-0259-0. [5] Wang F, Zhou J, Zhang Y, et al. The value of MicroRNA155 as a prognostic factor for survival in non-small cell lung cancer: a Meta-analysis[J]. PLoS One, 2015, 10(8): e0136889. DOI: 10.1371/journal.pone.0136889. [6] Wang R, Chen XF, Shu YQ. Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics[J]. Am J Cancer Res, 2015, 5(1): 32-51. [7] Chen WJ, Zhang EN, Zhong ZK, et al. MicroRNA-153 expression and prognosis in non-small cell lung cancer[J]. Int J Clin Exp Pathol, 2015, 8(7): 8671-8675. [8] Cameron L, Solomon B. New treatment options for ALK-rearranged non-small cell lung cancer[J]. Curr Treat Options Oncol, 2015, 16(10): 49. DOI: 10.1007/s11864015-0367-z. [9] Joshi P, Jeon YJ, Laganà A, et al. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC[J]. Proc Natl Acad Sci USA, 2015, 112(28): 8650-8655. DOI: 10.1073/pnas.1500886112. [10] Sun J, Song Y, Wang Z, et al. Clinical significance of promoter region hypermethylation of microRNA-148a in gastrointestinal cancers[J]. Onco Targets Ther, 2014, 7: 853-863. DOI: 10.2147/OTT.S60888. [11] Zhang SL, Liu L. microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1phosphate receptor 1[J]. Exp Ther Med, 2015, 9(2): 579-584. DOI: 10.3892/etm.2014.2137. [12] Ajdarkosh H, Dadpay M, Yahaghi E, et al. Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues[J]. Diagn Pathol, 2015, 10: 135. DOI: 10.1186/s13000-015-0371-4. [13] AlvarezGarcia I, Miska EA. MicroRNA functions in animal development and human disease[J]. Development, 2005, 132(21): 4653-4662. [14] Feber A, Xi LQ, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer[J]. J Thorac Cardiovasc Surg, 2008, 135(2): 255-260. DOI: 10.1016/j.jtcvs.2007.08.055. [15] Selbach M, Schwanh-usser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs[J]. Nature, 2008, 455(729): 58-63. DOI: 10.1038/nature07228. [16] Heo MJ, Kim YM, Koo JH, et al. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression[J]. Oncotarget, 2014, 5(9): 2792-2806. |
[1] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[2] | Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190. |
[3] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[4] | Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing.Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy[J]. Journal of International Oncology, 2023, 50(10): 600-607. |
[5] | Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing.MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2[J]. Journal of International Oncology, 2022, 49(4): 193-198. |
[6] | Jin Jiahui, Chen Cunhai, Ma Xuezhen.Effects of radiation-associated miRNA in radiotherapy for breast cancer[J]. Journal of International Oncology, 2022, 49(12): 735-738. |
[7] | Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei.Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer[J]. Journal of International Oncology, 2022, 49(11): 681-686. |
[8] | Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50. |
[9] | Hong Anlan, Cao Meng, Wang Yan, Fang Fang.Research progress on lncRNAs as members of ceRNA network in melanoma[J]. Journal of International Oncology, 2022, 49(1): 61-64. |
[10] | Liu Pei, Pu Jiaze, Huang Wen, Wang Fei.Expression differences of miR-200c, miR-19a and miR-155 in gefitinib sensitive and drug resistant NSCLC patients and their effects on prognosis[J]. Journal of International Oncology, 2021, 48(7): 409-414. |
[11] | Wang Yang, Liu Qian, Long Hui, Wu Qingming.Research status of fecal detection for colorectal cancer markers[J]. Journal of International Oncology, 2021, 48(7): 441-444. |
[12] | Cheng Yiming, Li Gang, Wang Zhenming, Lyu Qianwen, Li Shirong.Value of serum miR-196a-5p and miR-105-5p in differential diagnosis of benign and malignant pulmonary nodules[J]. Journal of International Oncology, 2021, 48(5): 282-286. |
[13] | Deng Bo'er, Kong Weimin.Epigenetic research progress of endometrial cancer[J]. Journal of International Oncology, 2021, 48(3): 184-188. |
[14] | Li Bingliang, Yang Ya, Huang Yingli, Si Wen, Li Xingwei, Zhang Yuanmin, Bian Jichao, Chen Yu.Effects of miR-20a-5p targeting KDM6B on the proliferation, migration and invasion of osteosarcoma cells[J]. Journal of International Oncology, 2021, 48(2): 65-73. |
[15] | He Miao, Fan Kui, Cao Fang.Epigenetics and drug resistance in lung cancer[J]. Journal of International Oncology, 2021, 48(10): 622-626. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||